Announcement • Apr 13
ImageneBio, Inc. announced that it expects to receive $29.999972 million in funding from a group of investors
ImageneBio, Inc. announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to issue 5,770,335 pre-funded warrants at an issue price of $5.199 for gross proceeds of $29,999,971.665 on April 12, 2026. The transaction includes participation from new investors, Coastlands Capital Partners LP, a fund managed by Coastlands Capital LP for 1,923,446 warrants, Trails Edge Biotechnology Master Fund, a fund managed by Trails Edge Capital Partners, LP for 1,346,412 warrants, OrbiMed Genesis Master Fund, L.P. for 384,689 warrants, OrbiMed Private Investments VI, LP for 336,603 warrants, funds managed by OrbiMed Advisors LLC, Biotechnology Value Fund L.P. for 276,086 warrants, Biotechnology Value Fund II, L.P. for 209,416 warrants, Biotechnology Value Trading Fund OS LP for 34,835 warrants, MSI BVF SPV, LLC for 8,610 warrants, funds managed by BVF Partners L.P., Funicular Fund, LP a fund managed by Cable Car Capital LLC for 480,861 warrants , Omega Fund VI, L.P., a fund managed by Omega Fund Management, LLC for 480,861 warrants, Stonepine Capital, L.P., a fund managed by Stonepine Capital Management LLC for 96,172 warrants, HIF Solitude Ltd for 84,780 warrants and Mission Pure Alpha Master LP for 107,564 warrants. The pre-funded warrant will have an exercise price of $0.001 per warrant share, subject to customary adjustments, and will be exercisable at any time after original issuance and will not expire until exercised in full. The closing of the private placement is anticipated to occur on or about April 14, 2026.